Suzhou Strivita Pharma Technology Co., Ltd.

— Leading Experts in DMPK & Early Toxicology Testing for Innovative Drug Development

Suzhou Strivita Pharma Technology Co., Ltd. operates as a specialized preclinical Contract Research Organization (CRO). We deliver integrated one-stop solutions encompassing DMPK (Drug Metabolism and Pharmacokinetics) profiling and non-clinical toxicology assessment, catering to pharmaceutical manufacturers, academic institutions and research laboratories worldwide.

Aligning with the full lifecycle development demands of novel therapeutics, we have established a comprehensive and interconnected technical service portfolio, spanning in vitro DMPK druggability evaluation, in vivo pharmacokinetic investigations, bioanalytical method establishment & sample quantification, as well as early-stage toxicological safety profiling. Backed by a cohort of seasoned technical experts, fully standardized laboratory infrastructure and an extensive track record of successfully delivered R&D programs, we furnish robust, regulation-compliant and time-efficient technical backing to translate fundamental pharmaceutical research into viable clinical trial submissions. Our integrated service framework enables partners to streamline their drug development timelines and mitigate R&D risks throughout the preclinical pipeline.